16 assets in Atherosclerotic Cardiovascular Disease

Therapeutic assets addressing Atherosclerotic Cardiovascular Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Umbellatine Atherosclerotic Cardiovascular Disease	China National Center for Cardiovascular Diseases	P4	BB (65)
Inclisiran Atherosclerotic Cardiovascular Disease	Novartis Pharmaceuticals	P3	B (60)
Maridebart Cafraglutide Atherosclerotic Cardiovascular Disease	Amgen	P3	B (60)
Orforglipron Atherosclerotic Cardiovascular Disease	Eli Lilly and Company	P3	B (60)
Retatrutide Atherosclerotic Cardiovascular Disease	Eli Lilly and Company	P3	B (60)
Tirzepatide Atherosclerotic Cardiovascular Disease	Brigham and Women's Hospital	P4	B (60)
[18F]AlF-OC Atherosclerotic Cardiovascular Disease	Universitaire Ziekenhuizen KU Leuven	P2	CCC (53)
Aspirin Atherosclerotic Cardiovascular Disease	Rajaie Cardiovascular Medical and Research Center	N/A	D (30)
Atorvastatin Atherosclerotic Cardiovascular Disease	Yonsei University	N/A	D (30)
Ezetimibe Atherosclerotic Cardiovascular Disease	Novartis Pharmaceuticals	N/A	D (30)
Pitavastatin Atherosclerotic Cardiovascular Disease	Yonsei University	N/A	D (30)